The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression

Molecular Cell

Volumn 16, Issue 4, 2004, Pages 631-639

  Minsky, Neri ^a   Oren, Moshe ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; LIGASE; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHROMATIN; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR MECHANICS; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; UBIQUITINATION;

CELL LINE; CELL LINE, TUMOR; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GLUTATHIONE TRANSFERASE; HISTONES; HUMANS; LUCIFERASES; NUCLEAR PROTEINS; PRECIPITIN TESTS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION, GENETIC; UBIQUITINS;

MAMMALIA;

EID: 8844232663     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2004.10.016     Document Type: Article

References (51)

1. Argentini M., Barboule N., Wasylyk B. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene. 20:2001;1267-1275
2. Berger S.L. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 12:2002;142-148
3. Brehm A., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 391:1998;597-601
4. Briggs S.D., Xiao T., Sun Z.W., Caldwell J.A., Shabanowitz J., Hunt D.F., Allis C.D., Strahl B.D. Gene silencing. trans-histone regulatory pathway in chromatin Nature. 418:2002;498
5. Chen J., Lin J., Levine A.J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1:1995;142-152
6. Citterio E., Papait R., Nicassio F., Vecchi M., Gomiero P., Mantovani R., Di Fiore P.P., Bonapace I.M. Np95 is a histone-binding protein endowed with ubiquitin ligase activity. Mol. Cell. Biol. 24:2004;2526-2535
7. Daniel J.A., Torok M.S., Sun Z.W., Schieltz D., Allis C.D., Yates J.R. 3rd, Grant P.A. Deubiquitylation of histone H2B by a yeast acetyltransferase complex regulates transcription. J. Biol. Chem. 16:2004;1867-1871
8. Daujat S., Neel H., Piette J. MDM2. life without p53 Trends Genet. 17:2001;459-464
9. Deb S.P. Function and dysfunction of the human oncoprotein MDM2. Front. Biosci. 7:2002;d235-d243
10. Dubs-Poterszman M.C., Tocque B., Wasylyk B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene. 11:1995;2445-2449
11. Dumaz N., Meek D.W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18:1999;7002-7010
12. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:2000;8945-8951
13. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564
14. Haviv I., Vaizel D., Shaul Y. The X protein of hepatitis B virus coactivates potent activation domains. Mol. Cell. Biol. 15:1995;1079-1085
15. Henry K.W., Wyce A., Lo W.S., Duggan L.J., Emre N.C., Kao C.F., Pillus L., Shilatifard A., Osley M.A., Berger S.L. Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev. 17:2003;2648-2663
16. Honda R., Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 19:2000;1473-1476
17. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27
18. Hsieh J.K., Chan F.S., O'Connor D.J., Mittnacht S., Zhong S., Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell. 3:1999;181-193
19. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21:2002;6236-6245
20. Jason L.J., Moore S.C., Lewis J.D., Lindsey G., Ausio J. Histone ubiquitylation. a tagging tail unfolds? Bioessays. 24:2002;166-174
21. Jenuwein T., Allis C.D. Translating the histone code. Science. 293:2001;1074-1080
22. Jin Y., Zeng S.X., Dai M.S., Yang X.J., Lu H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem. 277:2002;30838-30843
23. Juven-Gershon T., Shifman O., Unger T., Elkeles A., Haupt Y., Oren M. The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol. Cell. Biol. 18:1998;3974-3982
24. Kaeser M.D., Iggo R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA. 99:2002;95-100
25. Kaeser M.D., Iggo R.D. Promoter-specifc p53-dependent histone acetylation following DNA damage. Oncogene. 23:2004;4007-4013
26. Kobet E., Zeng X., Zhu Y., Keller D., Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA. 97:2000;12547-12552
27. Lambert P.F., Kashanchi F., Radonovich M.F., Shiekhattar R., Brady J.N. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273:1998;33048-33053
28. Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature. 389:1997;251-260
29. Mallery D.L., Vandenberg C.J., Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J. 21:2002;6755-6762
30. Michael D., Oren M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12:2002;53-59
31. Michael D., Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13:2003;49-58
32. Mundle S.D., Saberwal G. Evolving intricacies and implications of E2F1 regulation. FASEB J. 17:2003;569-574
33. Nielsen S.J., Schneider R., Bauer U.M., Bannister A.J., Morrison A., O'Carroll D., Firestein R., Cleary M., Jenuwein T., Herrera R.E., Kouzarides T. Rb targets histone H3 methylation and HP1 to promoters. Nature. 412:2001;561-565
34. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83
35. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860
36. Robzyk K., Recht J., Osley M.A. Rad6-dependent ubiquitylation of histone H2B in yeast. Science. 287:2000;501-504
37. Roest H.P., van Klaveren J., de Wit J., van Gurp C.G., Koken M.H., Vermey M., van Roijen J.H., Hoogerbrugge J.W., Vreeburg J.T., Baarends W.M., et al. Inactivation of the HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification. Cell. 86:1996;799-810
38. Shekhar M.P., Lyakhovich A., Visscher D.W., Heng H., Kondrat N. Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. Cancer Res. 62:2002;2115-2124
39. Shiio Y., Eisenman R.N. Histone sumoylation is associated with transcriptional repression. Proc. Natl. Acad. Sci. USA. 100:2003;13225-13230
40. Spotswood H.T., Turner B.M. An increasingly complex code. J. Clin. Invest. 110:2002;577-582
41. Stevaux O., Dyson N.J. A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 14:2003;684-691
42. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature. 403:2000;41-45
43. Sun Z.W., Allis C.D. Ubiquitylation of histone H2B regulates H3 methylation and gene silencing in yeast. Nature. 418:2002;104-108
44. Szak S.T., Mays D., Pietenpol J.A. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 21:2001;3375-3386
45. Thorne A.W., Sautiere P., Briand G., Crane-Robinson C. The structure of ubiquitylated histone H2B. EMBO J. 6:1987;1005-1010
46. Thut C.J., Goodrich J.A., Tjian R. Repression of p53-mediated transcription by MDM2. a dual mechanism Genes Dev. 11:1997;1974-1986
47. Vargas D.A., Takahashi S., Ronai Z. Mdm2. a regulator of cell growth and death Adv. Cancer Res. 89:2003;1-34
48. Vousden K.H., Lu X. Live or let die. the cell's response to p53 Nat. Rev. Cancer. 2:2002;594-604
49. Weinmann A.S., Farnham P.J. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods. 26:2002;37-47
50. Xia Y., Pao G.M., Chen H.W., Verma I.M., Hunter T. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J. Biol. Chem. 278:2003;5255-5263
51. Zhang Y. Transcriptional regulation by histone ubiquitylation and deubiquitylation. Genes Dev. 15:2003;2733-2740